Notably, Ebo TILs expressing elevated PD-1, T-cell immunoglobulin, mucin-domain containing-3 (TIM-3), and LAG-3 were associated with resistance to anti-PD therapy in NSCLC patients (106). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.